<DOC>
	<DOCNO>NCT00062439</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin , etoposide , docetaxel , use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining cisplatin etoposide radiation therapy may shrink tumor remove surgery . Giving docetaxel surgery may kill remain tumor cell . PURPOSE : This phase II trial study well give chemoradiotherapy together cisplatin etoposide follow surgery docetaxel work treat patient newly diagnose Pancoast tumor , type non-small cell lung cancer .</brief_summary>
	<brief_title>S0220 : Chemoradiotherapy Followed By Surgery Docetaxel Treating Patients With Pancoast Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility administer induction chemoradiotherapy comprise cisplatin etoposide follow surgical resection adjuvant docetaxel patient non-small cell lung cancer involve superior sulcus ( Pancoast tumor ) . - Determine overall survival patient treat regimen . - Determine time progression patient treat regimen . - Determine confirm unconfirmed complete partial response induction patient treat regimen . - Determine toxicity regimen patient . OUTLINE : - Induction chemoradiotherapy : Patients receive etoposide IV 1 hour day 1-5 29-33 cisplatin IV 1 hour day 1 , 8 , 29 , 36 . Patients also undergo concurrent radiotherapy daily 5 day week 5 week . Within 2-4 week completion induction chemoradiotherapy , patient undergo disease evaluation . Patients evidence local overall disease progression undergo thoracotomy within 3-7 week . Patients qualify surgery proceed consolidation chemotherapy within 3-8 week chemoradiotherapy complete . - Consolidation chemotherapy : Within 3-8 week thoracotomy , patient evidence disease progression receive docetaxel IV 1 hour day 1 . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . Patients follow 4-6 week , every 3 month 2 year , every 6 month 3 year . PROJECTED ACCRUAL : A total 45 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pancoast Syndrome</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer Any follow stage due involvement superior sulcus : Stage IIB ( T3 , N0 ) , IIIA ( T3 , N1 ) , IIIB ( T4 , N01 ) Newly diagnose Primary bronchogenic Must meet 1 follow tumor involvement criterion : An apical tumor associate Pancoast syndrome ( arm shoulder pain and/or neurologic finding correspond root C8 and/or T1 inferior trunk bronchial plexus without Horner 's syndrome ) without rib vertebral body involvement Superior sulcus tumor involvement chest wall ( T3 ) , usually rib 1 2 CT scan MRI , without associate Pancoast syndrome Superior sulcus tumor invasion vertebral body involvement subclavian vessel ( T4 ) CT scan MRI , without associate Pancoast syndrome No 1 parenchymal lesion lung lungs No involvement follow lymph node group determine mediastinal exploration* ( i.e. , mediastinoscopy , mediastinotomy , thoracoscopy , thoracotomy ) within past 42 day : Singlelevel multilevel ipsilateral contralateral mediastinal nodal ( N2 N3 ) disease mediastinoscopy , thoracoscopy , mediastinotomy , thoracotomy , transbronchial Wang needle biopsy , regardless whether enlarge node visible chest xray CT scan Supraclavicular ( scalene ) nod Any nodes evident physical exam must biopsied fine needle aspiration open biopsy Left upper lobe tumor leave vocal cord paralysis indirect laryngoscopy ( presumes N2 node AP window ) NOTE : *Mediastinal exploration require patient whose mediastinum negative positronemission tomography ( PET ) CT scan No pleural effusion except 1 follow criterion meet : Pleural effusion present mediastinoscopy thoracotomy negative cytology 2 separate thoracenteses Pleural effusion present exploratory stag thoracotomy , negative cytology single thoracentesis Present CT scan small tap No pericardial effusion superior vena cava syndrome No brain metastasis CT scan MRI No evidence distant metastatic disease bone scan PET Must candidate potential future pulmonary resection PATIENT CHARACTERISTICS : Age Not specify Performance status Zubrod 02 Patients Zubrod performance status 2 must albumin level least 0.85 time low limit normal weight loss great 10 % Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) * SGOT SGPT great 1.5 time ULN* NOTE : *Unless due document benign disease Renal Creatinine clearance least 50 mL/min Cardiovascular No myocardial infarction within past 3 month No active angina No unstable heart rhythms No clinically evident congestive heart failure Pulmonary Preresection FEV_1 least 2.0 L OR Predicted postresection FEV_1 great 1.0 L Other Not pregnant nursing Fertile patient must use effective contraception No uncontrolled peptic ulcer disease No grade 2 great sensory neuropathy No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent colonystimulating factor chemoradiotherapy course 1 consolidation therapy Chemotherapy No prior chemotherapy lung cancer Endocrine therapy Not specify Radiotherapy No prior radiotherapy neck thorax No concurrent intensitymodulated radiotherapy Surgery Prior exploratory thoracotomy allow diagnosis staging purpose Other No concurrent amifostine</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>